Bevacizumab plus paclitaxel optimization study with interventional maintenance endocrine therapy in advanced or metastatic ER-positive HER2-negative breast cancer-BOOSTER trial, a multicenter randomized phase II study
Latest Information Update: 10 Aug 2022
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary) ; Anastrozole; Exemestane; Fulvestrant; Goserelin; Letrozole; Leuprorelin
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms BOOSTER
- Sponsors Chugai Pharmaceutical
- 02 Aug 2022 Status changed from active, no longer recruiting to completed.
- 08 Apr 2022 Results published in the Lancet Oncology
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress